SAG
VRDN icon

SageView Advisory Group’s Viridian Therapeutics VRDN Stock Holding History

SageView Advisory Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-618
Closed -$19.2K – 2386
2025
Q4 		$19.2K Buy
+618
New +$16.9K ﹤0.01% 1468

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SageView Advisory Group's VRDN Position: Q1 2026 in Review

SageView Advisory Group sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 618 shares — an estimated $19.2K sold.

SageView Advisory Group first reported a position in VRDN in Q4 2025 and held it in 1 quarter. The position peaked at $19.2K in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • SageView Advisory Group reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 618 Viridian Therapeutics shares in Q1 2026, an estimated $19.2K.
  • SageView Advisory Group first reported a position in Viridian Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Viridian Therapeutics position peaked at $19.2K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.